Endocrine therapy plus zoledronic acid in premenopausal breast cancer [6]

New England Journal of Medicine

Volumn 360, Issue 22, 2009, Pages 2368-

  Berruti, Alfredo ^a   Buttigliero, Consuelo ^a   Dogliotti, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; VITAMIN D; ZOLEDRONIC ACID;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CELL PROLIFERATION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG MECHANISM; EARLY CANCER; ESTROGEN DEFICIENCY; HUMAN; LETTER; PREMENOPAUSE; PRIORITY JOURNAL; VITAMIN D DEFICIENCY; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 66249138071     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:49-59. (Pubitemid 43831958)
2. Nesby-O'Dell S, Scanlon KS, Cogswell ME, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002;76:187-192
3. Dick IM, Prince RL, Kelly JJ, Ho KK. Oestrogen effects on calcitriol levels in post-menopausal women: a comparison of oral versus transdermal administration. Clin Endocrinol (Oxf) 1995;43:219-224
4. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC. J Clin Oncol 2008;26:Suppl:9s. abstract.